Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Carlos Rivera-Caban

Vascular Surgery Ponce, PR Medical Doctor

NPI 1821233735 CMS profile 1393149

909 Ave Tito Castro Ste 602, Torre Medica San Lucas, Ponce, PR 00716

Open in the dashboard

General payments

$5,386

120 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Carlos Rivera-Caban of Ponce, PR is reported in the CMS Open Payments database as having received $5,386 across 120 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 52nd percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,120 31
2024 General $1,112 19
2023 General $1,193 19
2022 General $813 15
2021 General $319 15
2020 General $646 13
2019 General $182 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carlos Rivera-Caban
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Carlos Rivera-Caban were reported at $1,120. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Carlos Rivera-Caban Vascular Surgery median Middle half National median
2019 $182 $796 $226–$2,363 $163
2020 $646 $348 $118–$1,110 $114
2021 $319 $471 $158–$1,421 $132
2022 $813 $725 $222–$2,183 $149
2023 $1,193 $836 $257–$2,440 $160
2024 $1,112 $909 $252–$2,619 $164
2025 $1,120 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. W. L. Gore & Associates, Inc. $2,186 29 payments
  2. Medtronic, Inc. $1,918 44 payments
  3. Penumbra, Inc. $237 2 payments
  4. Becton, Dickinson and Company $106 4 payments
  5. Integra LifeSciences Corporation $96 1 payment
  6. Smith+Nephew, Inc. $90 5 payments
  7. Janssen Pharmaceuticals, Inc $85 4 payments
  8. Genentech USA, Inc. $83 1 payment
  9. Kerecis Limited $73 3 payments
  10. Cook Medical LLC $60 3 payments
  11. Other $451 24 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,096 119 payments
  2. Consulting Fee $290 1 payment
Products named General payments · program years 2019–2025
  1. ENDURANT IIS $1,454 30 payments
  2. GORE VIABAHN VBX Balloon Expandable Endo $936 11 payments
  3. GORE EXCLUDER AAA Endoprosthesis $486 4 payments
  4. Product in Development $290 1 payment
  5. Indigo System $237 2 payments
  6. C3 Delivery System $169 2 payments
  7. GORE VIABAHN Endoprosthesis with Heparin $164 2 payments
  8. Heli-FX EndoAnchor System $142 6 payments
  9. IN.PACT AV $131 1 payment
  10. VIABAHN VBX Balloon Expandable Endoprosthesis $96 4 payments
  11. Other $1,986 80 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

819

Median for Vascular Surgery: 122

Drug cost

$169,250

Median for Vascular Surgery: $14,135

Branded share of claims

70.3%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 154 $129,073
Xarelto Rivaroxaban Brand 36 $32,113
Clopidogrel Clopidogrel Bisulfate Brand 375 $4,696
Cilostazol Generic 80 $1,044
Triamcinolone Acetonide Generic 58 $770
Pregabalin Generic 21 $537
Gabapentin Generic 15 $347
Atorvastatin Calcium Generic 15 $305
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 11 $182
Hydrochlorothiazide Generic 18 $107

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 94 billing codes

Paid by Medicare

$97,306

Medicare's payments for the services billed

Medicare patients

209

Average age 75

Services billed

658

91 women, 118 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 68%
Chronic kidney disease 58%
Arthritis 58%
Diabetes 54%
COPD 46%
Heart failure 42%
Atrial fibrillation 36%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

120 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record